MedTrace Logo

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02497976 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2018-05-17

Study results available
· View outcomes & findings →

Summary

A Randomized, Double-blind, Placebo Controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome

Conditions

  • Cystitis, Interstitial

Interventions

BIOLOGICAL

Certolizumab pegol

400 mg

DRUG

Placebo

Normal saline

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • ICStudy, LLC

    lead OTHER

Principal Investigators

  • Philip C Bosch, MD · IC Study, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-15
Primary Completion
2017-04-16
Completion
2017-07-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02497976 on ClinicalTrials.gov